Regency Pharma Limited Pharmaceutical Import Profile — Mauritius (DGFT 2022–2026)

Name: Regency Pharma Limited Pharmaceutical Import Records from India — 16 Products, $8.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Regency Pharma Limited — Pharmaceutical Importer Profile (2026) | 16 Products, $8.9M Trade | TransData Nexus

Regency Pharma Limited

Pharmaceutical Importer · Mauritius · Antimalarial & Antiparasitic Focus · $8.9M Total Trade · DGFT Verified

Regency Pharma Limited is a pharmaceutical importer based in Mauritius with a total trade value of $8.9M across 16 products in 9 therapeutic categories. Based on 3,690 verified import shipments from Indian Customs (DGFT) records, Regency Pharma Limited is the #1 buyer in 4 products including Ivermectin, Empagliflozin, Extract. Regency Pharma Limited sources from 2 verified Indian suppliers, with Sava Healthcare Limited accounting for 98.2% of imports.

Regency Pharma Limited — Import Portfolio & Supplier Network

Regency Pharma Limited import network — 16 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Regency Pharma Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sava Healthcare Limited	$4.6M	9,998	98.2%
Hab Pharmaceuticals And Research Limited	$85.1K	2	1.8%

Regency Pharma Limited sources from 2 verified Indian suppliers across 1,003 distinct formulations. The sourcing is highly concentrated — Sava Healthcare Limited accounts for 98.2% of total imports, indicating a strategic single-source relationship.

What Formulations Does Regency Pharma Limited Import?

Formulation	Value	Ships
Ivermectol 12MG 48tab	$1.1M	82
Pharmaceuticalproducts-details as per	$691.8K	28
Apigat 5MG 30 TAB	$278.4K	66
Placentrex gel 0.25% / 0.1g w/w 20 GM	$173.1K	55
Triquilar 30mcg + 125mcg 21 TAB	$107.3K	35
Valclovir 500 MG 10 TAB	$86.4K	35
Orligal capsules (orlistat capsules	$85.1K	2
Centasava human placenta extract	$75.9K	2
Tugain solution 10% w/v 60 ML	$72.6K	68
Daparyl 10MG 10 TAB	$72.0K	35
Ivermectol 12MG 48tab	$59.1K	3
Rpigat 20MG 30 TAB	$58.1K	42
Apiban 5MG 100 TAB	$56.0K	5
Trifree	$50.0K	1
Trifree - levonorgestrel and	$50.0K	1

Regency Pharma Limited imports 1,003 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 16 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ivermectin	Antimalarial & Antiparasitic	$2.5M	363	28.4%	1
2	Empagliflozin	Diabetes & Endocrine	$1.3M	688	15.0%	1
3	Dapagliflozin	Advanced Diabetes Medications	$1.3M	692	2.7%	7
4	Apixaban	Cardiovascular	$1.3M	306	0.7%	19
5	Extract	Ayurvedic & Herbal Products	$806.6K	220	6.6%	1
6	Semaglutide	Advanced Diabetes Medications	$435.7K	196	7.5%	4
7	Torsemide	Diuretics	$308.1K	417	1.7%	7
8	Cyclosporine	Immunosuppressants	$276.0K	320	2.3%	7
9	Tiotropium	Respiratory	$180.7K	74	0.3%	11
10	Asava	Ayurvedic & Herbal Products	$152.4K	6	33.3%	1
11	Pyrantel	Antimalarial & Antiparasitic	$148.3K	36	4.5%	6
12	Linagliptin	Advanced Diabetes Medications	$71.9K	70	1.8%	4
13	Acarbose	Advanced Diabetes Medications	$37.2K	89	0.6%	15
14	Canagliflozin	Advanced Diabetes Medications	$24.1K	111	2.7%	9
15	Saxagliptin	Advanced Diabetes Medications	$20.5K	93	0.4%	6
16	Catheter	Medical Devices & Diagnostics	$1.0K	9	0.9%	7

Regency Pharma Limited imports 16 pharmaceutical products across 9 categories into Mauritius totaling $8.9M. The company is the #1 buyer for 4 products: Ivermectin, Empagliflozin, Extract, Asava.

Regency Pharma Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Regency Pharma Limited is a pharmaceutical importer and distributor based in Mauritius, specializing in the procurement and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company operates as a primary wholesaler, sourcing a diverse range of pharmaceutical products to meet the needs of the Mauritian healthcare sector. Headquartered at Warehouse No.1, BPML Freeport Zone 9, Plaine Magnien SSR International, Mauritius, Regency Pharma Limited plays a pivotal role in ensuring the availability of essential medications across the island nation.

Established in 1991, Regency Pharma Limited has developed a robust network of suppliers and partners, primarily focusing on imports from India. The company's extensive import portfolio encompasses 16 distinct products across nine therapeutic categories, reflecting its commitment to addressing a wide array of medical needs within Mauritius. This strategic sourcing approach underscores Regency Pharma Limited's dedication to providing comprehensive pharmaceutical solutions to the Mauritian market.

2Distribution Network

Regency Pharma Limited's distribution network is strategically located to facilitate efficient logistics and timely delivery of pharmaceutical products throughout Mauritius. The company's primary warehouse, situated at Warehouse No.1, BPML Freeport Zone 9, Plaine Magnien SSR International, serves as the central hub for inventory management and distribution operations. This location offers proximity to key transportation routes, enhancing the company's ability to manage and distribute products effectively across the island.

While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, Regency Pharma Limited's centralized distribution model suggests a focus on optimizing supply chain operations to meet the demands of the Mauritian healthcare sector. The company's strategic positioning within the Freeport Zone indicates potential advantages in terms of customs procedures and import-export facilitation, contributing to the overall efficiency of its distribution network.

3Industry Role

In the pharmaceutical supply chain of Mauritius, Regency Pharma Limited functions as a primary wholesaler, sourcing a diverse array of finished pharmaceutical formulations from international suppliers, predominantly from India. The company's extensive import activities, encompassing 16 products across nine therapeutic categories, highlight its significant role in ensuring the availability of essential medications within the Mauritian market. By acting as a conduit between international manufacturers and local healthcare providers, Regency Pharma Limited plays a crucial role in maintaining the supply of critical pharmaceutical products to meet the needs of the Mauritian population.

The company's position as a primary wholesaler is further emphasized by its substantial import volume, with a total import value of $8.9 million USD and 3,690 shipments recorded from 2022 to 2026. This scale of operations underscores Regency Pharma Limited's capacity to manage and distribute a wide range of pharmaceutical products, reinforcing its integral position within the Mauritian pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Regency Pharma Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Regency Pharma Limited exhibits a high degree of sourcing concentration, with a significant majority of its pharmaceutical imports originating from India. The company's total import value from India stands at $8.9 million USD, encompassing 3,690 shipments across 16 products. This sourcing strategy underscores India's pivotal role as a supplier of pharmaceutical products to Mauritius, aligning with the broader trend of Indian pharmaceuticals dominating the Mauritian market.

The concentration of imports from a single country, particularly one as dominant as India in the Mauritian pharmaceutical market, presents both strategic advantages and potential risks. On the positive side, this focused sourcing approach may lead to streamlined logistics, favorable pricing, and established supplier relationships. However, it also exposes Regency Pharma Limited to risks associated with geopolitical factors, regulatory changes, and supply chain disruptions within India. The company's reliance on a limited number of suppliers—Sava Healthcare Limited and HAB Pharmaceuticals and Research Limited—further intensifies this concentration risk. While the data indicates a stable relationship with these suppliers, any disruptions could significantly impact Regency Pharma Limited's ability to meet the pharmaceutical needs of the Mauritian market.

2Supply Chain Resilience

Importing Pharmaceuticals into Mauritius — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Mauritius

1Regulatory Authority & Framework

In Mauritius, the regulation of pharmaceutical products is primarily governed by the Pharmacy Act of 1983 and the Consumer Protection (Price and Supplies Control) Act of 1998. The Pharmacy Act 1983 establishes the legal framework for the authorization, marketing, sale, and supply of pharmaceutical products, defining "pharmaceutical product" as any drug, medicine, preparation, poison, or therapeutic substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals.

The Consumer Protection (Price and Supplies Control) Act of 1998 complements the Pharmacy Act by regulating the pricing and supply of pharmaceutical products, ensuring that consumers have access to essential medications at fair prices. These legislative frameworks collectively aim to maintain the quality, safety, and efficacy of pharmaceutical products available in Mauritius, safeguarding public health and ensuring the integrity of the pharmaceutical supply chain.

2Import Licensing & GMP

Pharmaceutical products imported into Mauritius must comply with the regulations set forth by the Pharmacy Board, operating under the Ministry of Health and Wellness. Only wholesalers licensed by the Pharmacy Board are authorized to import pharmaceutical products, ensuring that all imported medications meet the required standards for quality and safety.

Regency Pharma Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Regency Pharma Limited's product strategy focuses on importing a diverse range of pharmaceutical formulations across multiple therapeutic categories, including antimalarial and antiparasitic agents, advanced diabetes medications, and other diabetes and endocrine treatments. This strategic focus aligns with the prevalent health concerns in Mauritius, where diseases such as malaria

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Regency Pharma Limited

What products does Regency Pharma Limited import from India?

Regency Pharma Limited imports 16 pharmaceutical products across 9 categories. Top imports: Ivermectin ($2.5M), Empagliflozin ($1.3M), Dapagliflozin ($1.3M), Apixaban ($1.3M), Extract ($806.6K).

Who supplies pharmaceuticals to Regency Pharma Limited from India?

Regency Pharma Limited sources from 2 verified Indian suppliers. The primary supplier is Sava Healthcare Limited (98.2% of imports, $4.6M).

What is Regency Pharma Limited's total pharmaceutical import value?

Regency Pharma Limited's total pharmaceutical import value from India is $8.9M, based on 3,690 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Regency Pharma Limited focus on?

Regency Pharma Limited imports across 9 categories. The largest: Antimalarial & Antiparasitic (29.9%), Advanced Diabetes Medications (21.7%), Diabetes & Endocrine (15.1%).

Get Full Regency Pharma Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.